PDF herunterladen
Klin Monbl Augenheilkd 2011; 228(9): 780-792
DOI: 10.1055/s-0029-1246068
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Maligne epibulbäre Tumoren: Neue Strategien in Diagnostik und Therapie

Malignant Epibulbar Tumours: New Strategies in Diagnostics and TherapyH. Westekemper1 , M. Schallenberg1 , A. Tomaszewski1 , H. Nückel2 , W. Sauerwein3 , D. Meller1 , K. Steuhl1
  • 1Zentrum für Augenheilkunde, Klinik für Erkrankungen des vorderen Augenabschnitts, Universitätsklinikum Essen
  • 2Zentrum für Innere Medizin, Klinik für Hämatologie, Universitätsklinikum Essen
  • 3Klinik für Strahlentherapie, Universitätsklinikum Essen
Weitere Informationen

Publikationsverlauf

Eingegangen: 11.7.2010

Angenommen: 18.1.2011

Publikationsdatum:
12. April 2011 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

In dieser Übersichtsarbeit werden die wichtigsten malignen konjunktivalen Neoplasien abgehandelt und die komplexe Diagnostik und multimodale Therapie für die verschiedenen Tumorentitäten zusammengefasst. Das Bindehautmelanom stellt vor allem in seiner Abgrenzung zu benignen melanozytären Tumoren der Bindehaut eine diagnostische Herausforderung dar. Konsequentes chirurgisches Vorgehen gepaart mit einem schlüssigen adjuvanten Therapiekonzept für die jeweilige Tumorsituation sind Basis einer kurativen Therapie. Konjunktivale intraepitheliale Neoplasien (CIN) sind in ihrer mittleren und schweren Form Vorstufen des invasiven Plattenepithelkarzinoms (PE-Ca). Problematisch ist hierbei die häufig großflächige Ausbreitung des invasiven Tumors oder begleitender CINs, die eine R 0-Resektion erschweren oder unmöglich machen. Adjuvanten bzw. begleitenden Therapien kommt daher eine besondere Bedeutung zu, um Tumorkontrolle und Funktionserhalt des Auges zu erreichen. Lymphome sind die häufigsten malignen primären Tumoren der Augenhöhle und der okulären Adnexe. In diesem Zusammenhang können die Lymphome als primäre oder sekundäre Tumoren in den Konjunktiven, der Tränendrüse, dem orbitalen Fett, Augenlid und Tränensack auftreten. Die häufigste Manifestation der okulären MALT-Lymphome sind die Konjunktiven mit 20 – 33 % von allen epibulbären Lymphomen. Mehr als 75 % der okulären Lymphompatienten entwickeln eine einzige lymphomatöse Läsion. Eine Immunphänotypisierung ermöglicht die genaue Differenzierung der Lymphomentitäten. In der Pathogenese werden heute auch infektiologische Faktoren, z. B. durch Chlamydia psittaci berücksichtigt. Zuletzt wird aus strahlentherapeutischer Sicht eine umfassende Übersicht über die an der Konjunktiva sinnvoll einsetzbaren Therapieverfahren gegeben.

Abstract

In this article we discuss the complex diagnostic approaches and therapeutic options for the most important conjunctival malignancies. Conjunctival melanoma can be a diagnostic challenge as it can be difficult to distinguish from benign melanocytic conjunctival tumours. Complete surgical excision accompanied by a coherent adjuvant concept is the key for a curative therapy. Moderate and severe conjunctival intraepithelial neoplasias (CIN) are precancerous lesions and can progress to invasive squamous cell carcinoma. The involvement of large parts of the ocular surface can prevent an R 0-resection. Adjuvant therapeutic concepts are therefore especially important to gain tumour control and preserve the function of the affected eye. Lymphomas are the most common malignant primary tumours of the orbit and ocular adnexa. They can present as primary or secondary tumours of the conjunctiva, the lacrimal gland, the orbital fat, the eye lid or the lacrimal sac. The most common manifestation site of ocular MALT lymphoma is the conjunctiva with 20 – 33 % of all epibulbar lymphomas. More than 75 % of ocular lymphoma patients develop only one lymphomatous lesion. Immunophenotyping allows the exact differentiation between the lymphoma entities. Infectious agents (e. g., Chlamydia psittaci) seem to play a role in the pathogenesis. An overview over radiotherapeutic approaches that are conclusively applicable at the conjunctiva completes the article.

Schlüsselwörter

Bindehautmelanom - Plattenepithelkarzinom/CIN - epibulbäres Lymphom - topische Chemotherapie - Radiotherapie

Key words

conjunctival melanoma - squamous cell carcinoma/CIN - epibulbar lymphoma - topical chemotherapy - radiotherapy

Literatur

  • 1 Seregard S. Conjunctival melanoma: major review.  Surv of Ophthalmol. 1998;  42 321-350
    Google Scholar
  • 2 Shields C L. Conjunctival melanoma: risk factors for recurrences, exenteration, metastasis and death in 150 consecutive patients.  Trans Am Ophthalmol Soc. 2000;  98 471-492
    Google Scholar
  • 3 Tuomaala S, Eskelin S, Tarkkanen A et al. Population-Based Assessment of Clinical Characteristics Predicting Outcome of Conjunctival Melanoma in Whites.  Invest Ophthalmol Vis Sci. 2002;  43 3399-3408
    Google Scholar
  • 4 Missotten G, Keijser S, Keizer R JWD et al. Conjunctival Melanoma in The Netherlands: A Nationwide Study.  Invest Ophthalmol Vis Sci. 2005;  46 75-82
    Google Scholar
  • 5 Jakobiec F, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva.  Ophthalmology. 1989;  96 (2) 147-166
    Google Scholar
  • 6 Shields J, Shields C, Mashayekhi A et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture.  Ophthalmology. 2008;  115 (3) 511-519
    Google Scholar
  • 7 Folberg R, McLean I, Zimmerman L. Conjunctival melanosis and melanoma.  Ophthalmology. 1984;  91 673-678
    Google Scholar
  • 8 Damato B, Coupland S. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging.  Clin Experiment Ophthalmol. 2008;  36 (8) 786-795
    Google Scholar
  • 9 Rudolph P. Melanocyte tumors. Classical and new diagnostic possibilities.  Pathologe. 2002;  23 (1) 89-96
    Google Scholar
  • 10 Lommatzsch P K, Werschnik C. Malignant conjunctival melanoma. Clinical review with recommendations for diagnosis, therapy and follow-up.  Klin Monatsbl Augenheilkd. 2002;  219 (10) 710-721
    Google Scholar
  • 11 Damato B, Coupland S. Clinical mapping of conjunctival melanomas.  Br J Ophthalmol. 2008;  92 1545-1549
    Google Scholar
  • 12 Steuhl K, Rohrbach J, Knorr M et al. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors.  Ophthalmology. 1993;  100 (2) 208-215
    Google Scholar
  • 13 Jakobiec F, Bhat P, Colby K. Immunohistochemical studies of conjunctival nevi and melanomas.  Arch Ophthalmol. 2010;  128 (2) 174-183
    Google Scholar
  • 14 Keijser I, Missotten G, Bonfrer J et al. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.  Br J Ophthalmol. 2006;  90 213-217
    Google Scholar
  • 15 Sharara N, Alexander R, Luthert P et al. Differential immunoreactivity of melanocytic lesions of the conjunctiva.  Histopathology. 2001;  39 (4) 426-431
    Google Scholar
  • 16 Furusato E, Hidayat A, Man Y et al. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.  Arch Ophthalmol. 2009;  127 (8) 964-969
    Google Scholar
  • 17 Westekemper H, Karimi S, Süsskind D et al. Expression of MCSP and PRAME in conjunctival melanoma.  Br J Ophthalmol. 2010;  94 (10) 1322-1327
    Google Scholar
  • 18 Westekemper H, Karimi S, Süsskind D et al. Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma.  Br J Ophthalmol. 2010;  [Epub ahead of print] DOI: 10.1136/bjo.2010.183939
    Google Scholar
  • 19 Werschnik C, Lommatzsch P K. Long-term follow-up of patients with conjunctival melanoma.  Am J Clin Oncol. 2002;  25 (3) 248-255
    Google Scholar
  • 20 Anastassiou G, Heiligenhaus A, Bechrakis N et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study.  Br J Ophthalmol. 2002;  86 163-167
    Google Scholar
  • 21 Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969 – 1991.  Acta Ophthalmol Scand. 1992;  70 289-296
    Google Scholar
  • 22 Folberg R, McLean I W, Zimmermann L E. Malignant melanoma of the conjunctiva.  Hum Pathol. 1985;  16 136-143
    Google Scholar
  • 23 Tuomaala S, Kivelä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy.  Ophthalmology. 2004;  111 (4) 816-821
    Google Scholar
  • 24 Savar A, Ross M, Prieto V et al. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients.  Ophthalmology. 2009;  116 (11) 2217-2223
    Google Scholar
  • 25 Tuomaala S, Kivelä T. Sentinel lymph node biopsy guidelines for conjunctival melanoma.  Melanoma Res. 2008;  18 (3) 235
    Google Scholar
  • 26 Amato M, Esmaeli B, Ahmadi M et al. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies.  Ophthal Plast Reconstr Surg. 2003;  19 (2) 102-106
    Google Scholar
  • 27 Esmaeli B, Eicher S, Popp J et al. Sentinel lymph node biopsy for conjunctival melanoma.  Ophthal Plast Reconstr Surg. 2001;  17 (6) 436-442
    Google Scholar
  • 28 Esmaeli B. Sentinel node biopsy as a tool for accurate staging of eyelid and conjunctival malignancies.  Curr Opin Ophthalmol. 2002;  13 (5) 317-323
    Google Scholar
  • 29 Brownstein S. Malignant Melanoma of the Conjunctiva.  Cancer Control. 2004;  11 (5) 310-317
    Google Scholar
  • 30 Shields C L, Shields J A. Tumors of the Conjunctiva and Cornea.  Surv of Ophthalmol. 2004;  49 (1) 3-24
    Google Scholar
  • 31 Finger P. ‘‘Finger-tip’’ cryotherapy probes: treatment of squamous and melanocytic conjunctival neoplasia.  Br J Ophthalmol. 2005;  89 942-945
    Google Scholar
  • 32 Damato B, Coupland S. Management of conjunctival melanoma.  Expert Rev Anticancer Ther. 2009;  9 (9) 1227-1239
    Google Scholar
  • 33 Zehetmayer M, Menapace R, Kulnig W. Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibulbar malignancies.  Ophthalmologica. 1993;  207 (3) 133-139
    Google Scholar
  • 34 Wuestemeyer H, Sauerwein W, Meller D et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 438-446
    Google Scholar
  • 35 Frucht-Pery J, Pe’er J. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia.  Arch Ophthalmol. 1996;  114 (10) 1261-1264
    Google Scholar
  • 36 Kurli M, Finger P. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 (11) 1108-1114
    Google Scholar
  • 37 Finger P, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.  Br J Ophthalmol. 1998;  82 476-479
    Google Scholar
  • 38 Schallenberg M, Niederdräing N, Steuhl K et al. Topical Mitomycin C as a therapy of conjunctival tumours.  Ophthalmologe. 2008;  105 (8) 777-784
    Google Scholar
  • 39 Basti S, Macsai M. Ocular surface neoplasia, a review.  Cornea. 2003;  22 (7) 687-704
    Google Scholar
  • 40 Lee G, Hirst L. Ocular surface squamous neoplasia.  Surv Ophthalmol. 1995;  39 (6) 429-450
    Google Scholar
  • 41 Meta M, Fay A. Squamous cell carcinoma of the eyelid and the conjunctiva.  Int Ophthalmol Clinics. 2009;  49 (1) 111-121
    Google Scholar
  • 42 Shields C, Manchandia A, Subbiah R et al. Pigmented squamous cell carcinoma in situ of the conjunctiva in 5 cases.  Ophthalmology. 2008;  115 1673-1678
    Google Scholar
  • 43 Holbach L, Pogorelov P, Kruse F. Differentialdiagnose und Therapieoptionen bei Tumoren der Konjunktiva.  Ophthalmologe. 2007;  254 521-539
    Google Scholar
  • 44 Verma V, Shen D, Sieving P C et al. The role of infectious agents in the etiology of ocular adnexal neoplasia.  Surv Ophthalmol. 2008;  53 (4) 312-331
    Google Scholar
  • 45 Crum C P, Ikenberg H, Richart R M et al. Human papillomavirus type 16 and early cervical neoplasia.  N Engl J Med. 1984;  310 (14) 880-883
    Google Scholar
  • 46 Scott I U, Karp C L, Nuovo G J. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia.  Ophthalmology. 2002;  109 (3) 542-547
    Google Scholar
  • 47 Shields J, Shields C, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture.  Arch Ophthalmol. 1997;  115 (6) 808-815
    Google Scholar
  • 48 Beutel J, Sommer K, Gottschalk S et al. Squamous cell carcinoma of the conjunctiva with orbital invasion: orbital exenteration or minimally invasive procedure?.  Ophthalmologe. 2006;  103 (8) 693-697
    Google Scholar
  • 49 Schrader S, Notara M, Beaconsfield M et al. Tissue engineering for conjunctival reconstruction: established methods and future outlooks.  Curr Eye Res. 2009;  34 (11) 913-924
    Google Scholar
  • 50 Peksayar G, Altan-Yaycioglu R, Onal S. Excision and cryosurgery in the treatment of conjunctival malignant epithelial tumours.  Eye (Lond). 2003;  17 (2) 228-232
    Google Scholar
  • 51 Tunc M, Char D, Crawford B et al. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases.  Br J Ophthalmol. 1999;  83 (1) 98-103
    Google Scholar
  • 52 Caujolle J, Maschi C, Chauvel P et al. Surgery and additional protontherapy for treatment of invasive and recurrent squamous cell carcinomas: technique and preliminary results.  J Fr Ophtalmol. 2009;  32 (10) 707-714
    Google Scholar
  • 53 Frucht-Pery J, Rozenman Y. Mitomycin C therapy for corneal intraepithelial neoplasia.  Am J Ophthalmol. 1994;  117 (2) 164-168
    Google Scholar
  • 54 Wilson M W, Hungerford J L, George S M et al. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.  Am J Ophthalmol. 1997;  124 (3) 303-311
    Google Scholar
  • 55 Dudney B W, Malecha M A. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.  Am J Ophthalmol. 2004;  137 (5) 950-951
    Google Scholar
  • 56 Khong J J, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.  Br J Ophthalmol. 2006;  90 (7) 819-822
    Google Scholar
  • 57 Huerva V, Mateo A J, Mangues I et al. Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia.  Cornea. 2006;  25 (10) 1220-1223
    Google Scholar
  • 58 Smith M, Trousdale M D, Rao N A et al. Lack of toxicity of a topical recombinant interferon alpha.  Cornea. 1989;  8 (1) 58-61
    Google Scholar
  • 59 Giaconi J, Karp C. Current treatment options for conjunctival and corneal intraepithelial neoplasia.  Ocul Surf. 2003;  1 (2) 66-73
    Google Scholar
  • 60 Margo C E, Mulla Z D. Malignant tumors of the orbit. Analysis of the Florida Cancer Registry.  Ophthalmology. 1998;  105 (1) 185-190
    Google Scholar
  • 61 Decaudin D, Cremoux de P, Vincent-Salomon A et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options.  Blood. 2006;  108 (5) 1451-1460
    Google Scholar
  • 62 Sasai K, Yamabe H, Dodo Y et al. Non-Hodgkin’s lymphoma of the ocular adnexa.  Acta Oncol. 2001;  40 (4) 485-490
    Google Scholar
  • 63 Moslehi R, Devesa S S, Schairer C et al. Rapidly increasing incidence of ocular non-hodgkin lymphoma.  J Natl Cancer Inst. 2006;  98 (13) 936-939
    Google Scholar
  • 64 Coupland S E, Jaehne D, Hummel M et al. The tale and molecular trail of a disseminated ocular adnexal malt lymphoma.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 (7) 1055-1059
    Google Scholar
  • 65 Knowles D M, Jakobiec F A, McNally L et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987.  Hum Pathol. 1990;  21 (9) 959-973
    Google Scholar
  • 66 Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors.  Hematol Oncol. 2004;  22 (4) 143-158
    Google Scholar
  • 67 Martinet S, Ozsahin M, Belkacemi Y et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy.  Int J Radiat Oncol Biol Phys. 2003;  55 (4) 892-898
    Google Scholar
  • 68 Rosado M F, Byrne G E Jr, Ding F et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci.  Blood. 2006;  107 (2) 467-472
    Google Scholar
  • 69 Wotherspoon A C, Ortiz-Hidalgo C, Falzon M R et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma.  Lancet. 1991;  338 (8776) 1175-1176
    Google Scholar
  • 70 Ferreri A J, Guidoboni M, Ponzoni M et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.  J Natl Cancer Inst. 2004;  96 (8) 586-594
    Google Scholar
  • 71 Ferreri A J, Dolcetti R, Dognini G P et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study.  Int J Cancer. 2008;  123 (5) 1089-1093
    Google Scholar
  • 72 Decaudin D, Dolcetti R, Cremoux de P et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?.  Anticancer Drugs. 2008;  19 (8) 761-765
    Google Scholar
  • 73 Chanudet E, Zhou Y, Bacon C M et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions.  J Pathol. 2006;  209 (3) 344-351
    Google Scholar
  • 74 Ferreri A J, Ponzoni M, Dognini G P et al. Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial.  Ann Oncol. 2006;  17 (11) 1721-1722
    Google Scholar
  • 75 Ponzoni M, Ferreri A J, Guidoboni M et al. Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods.  Clin Cancer Res. 2008;  14 (18) 5794-5800
    Google Scholar
  • 76 Auw-Hadrich C, Gobel N, Illerhaus G. Infectious agents in ocular adnexal tumours.  Klin Monatsbl Augenheilkd. 2010;  227 (7) 530-537
    Google Scholar
  • 77 Hatef E, Roberts D, McLaughlin P et al. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.  Arch Ophthalmol. 2007;  125 (12) 1663-1667
    Google Scholar
  • 78 Stacy R, Jakobiec F, Schoenfield L et al. Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa.  Am J Ophthalmol. 2010;  150 (3) 412-426
    Google Scholar
  • 79 Spraul C, Mattfeldt T, Lang G. Conjunctival pseudolymphoma in infectious mononucleosis.  Klin Monatsbl Augenheilkd. 1999;  215 (1) 68-69
    Google Scholar
  • 80 Feinberg A, Spraul C, Holden J et al. Conjunctival lymphocytic infiltrates associated with Epstein-Barr virus.  Ophthalmology. 2000;  107 (1) 159-163
    Google Scholar
  • 81 Tanimoto K, Kaneko A, Suzuki S et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma.  Ann Oncol. 2006;  17 (1) 135-140
    Google Scholar
  • 82 Bardenstein D S. Ocular adnexal lymphoma: classification, clinical disease, and molecular biology.  Ophthalmol Clin North Am. 2005;  18 (1) 187-197
    Google Scholar
  • 83 Ferreri A J, Ponzoni M, Guidoboni M et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.  J Natl Cancer Inst. 2006;  98 (19) 1375-1382
    Google Scholar
  • 84 Ferreri A J, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.  Haematologica. 2005;  90 (11) 1578-1579
    Google Scholar
  • 85 Rigacci L, Nassi L, Puccioni M et al. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.  Ann Hematol. 2007;  86 (8) 565-568
    Google Scholar
  • 86 Nückel H, Meller D, Steuhl K P et al. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.  Eur J Haematol. 2004;  73 258-262
    Google Scholar
  • 87 Esmaeli B, Murray J L, Ahmadi M A et al. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.  Arch Ophthalmol. 2002;  120 (9) 1225-1227
    Google Scholar
  • 88 Esmaeli B, McLaughlin P, Pro B et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.  Ann Oncol. 2009;  20 (4) 709-914
    Google Scholar
  • 89 Ferreri A J, Govi S, Colucci A et al. Intralesional Rituximab A New Therapeutic Approach for Patients with Conjunctival Lymphomas.  Ophthalmology. 2011;  118 (1) 24-28
    Google Scholar
  • 90 Blasi M A, Gherlinzoni F, Calvisi G et al. Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report.  Ophthalmology. 2001;  108 (3) 559-562
    Google Scholar
  • 91 Lachapelle K R, Rathee R, Kratky V et al. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.  Arch Ophthalmol. 2000;  118 (2) 284-285
    Google Scholar
  • 92 Fung C Y, Tarbell N J, Lucarelli M J et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes.  Int J Radiat Oncol Biol Phys. 2003;  57 (5) 1382-1391
    Google Scholar
  • 93 Meunier J, Lumbroso-Le Rouic L, Dendale R et al. Conjunctival low-grade non-Hodgkin’s lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors.  Leuk Lymphoma. 2006;  47 (7) 1295-1305
    Google Scholar
  • 94 Kearsley J H, Fitchew R S, Taylor R G. Adjunctive radiotherapy with strontium-90 in the treatment of conjunctival squamous cell carcinoma.  Int J Radiat Oncol Biol Phys. 1988;  14 (3) 435-443
    Google Scholar
  • 95 Sekundo W, Roggenkamper P, Fischer H P et al. Primary conjunctival rhabdomyosarcoma: 2.5 years’ follow-up after combined chemotherapy and brachytherapy.  Graefes Arch Clin Exp Ophthalmol. 1998;  236 (11) 873-875
    Google Scholar
  • 96 Chauvel P, Caujolle J, Sauerwein W. et al .Protontherapy as a possible salvage treatment for conjunctival melanomas. Frezotti R, Balestrazzi E, Flaco L, (eds) Bologna: Monduzzi Editore; 1994: 177-181
    Google Scholar
  • 97 Westekemper H, Anastassiou G, Sauerwein W et al. Analyse der okulären Oberfläche nach Protonenbestrahlung bei malignem Melanom der Bindehaut.  Ophthalmologe. 2006;  103 588-595
    Google Scholar
  • 98 Sauerwein W, Hoederath A, Sack H. Radiotherapy of primary orbital lymphomas.  Front Radiat Ther Oncol. 1997;  30 192-194
    Google Scholar
  • 99 Sauerwein W, Stannard C. Auge und Orbita. Bamberg M, Molls M, Sack H, (eds) Radioonkologie Band 2: Klinik.. München, Wien, New York: W. Zuckerschwerdt Verlag; 2009: 294-316
    Google Scholar
  • 100 Brualla L, Palanco-Zamora R, Wittig A et al. Comparison between PENELOPE and electron Monte Carlo simulations of electron fields used in the treatment of conjunctival lymphoma.  Phys Med Biol. 2009;  54 (18) 5469-5481
    Google Scholar

Prof. Dr. Klaus P. Steuhl

Klinik für Erkrankungen des vorderen Augenabschnitts, Universitäts-Augenklinik

Hufelandstr. 55

45122 Essen

Telefon:  ++ 49/2 01/7 23 23 71/5

Fax:  ++ 49/2 01/7 23 57 48

eMail: klaus-peter.steuhl@uk-essen.de